{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:34Z","timestamp":1793291614904,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01143-2","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:33:46Z","timestamp":1785771226000},"page":"968-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0126-4731","authenticated-orcid":false,"given":"Francesco","family":"Ditonno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-3206","authenticated-orcid":false,"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-4550","authenticated-orcid":false,"given":"Rui M.","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2719","authenticated-orcid":false,"given":"Luca","family":"Cindolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-3005","authenticated-orcid":false,"given":"Ugo","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-7725","authenticated-orcid":false,"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-4601","authenticated-orcid":false,"given":"Riccardo","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/MOU.0000000000000672","volume":"29","author":"B Hanna","year":"2019","unstructured":"Hanna B, Ranasinghe W, Lawrentschuk N. Risk stratification and avoiding overtreatment in localized prostate cancer. Curr Opin Urol. 2019;29:612\u20139. https:\/\/doi.org\/10.1097\/MOU.0000000000000672.","journal-title":"Curr Opin Urol"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.urolonc.2021.05.016","volume":"39","author":"DE Hansel","year":"2021","unstructured":"Hansel DE. A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers. Urologic Oncol. 2021;39:582\u201394. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.016.","journal-title":"Urologic Oncol"},{"key":"1143_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/modpathol.3800054","volume":"17","author":"PA Humphrey","year":"2004","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17:292\u2013306. https:\/\/doi.org\/10.1038\/modpathol.3800054.","journal-title":"Mod Pathol"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/JU.0000000000001011","volume":"204","author":"C Bronkema","year":"2020","unstructured":"Bronkema C, Arora S, Sood A, Dalela D, Keeley J, Borchert A, et al. Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis. J Urol. 2020;204:260\u20136. https:\/\/doi.org\/10.1097\/JU.0000000000001011.","journal-title":"J Urol"},{"key":"1143_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/JU.0000000000001290","volume":"204","author":"N Miura","year":"2020","unstructured":"Miura N, Mori K, Mostafaei H, Quhal F, Motlagh RS, Pradere B, et al. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. J Urol. 2020;204:909\u201317. https:\/\/doi.org\/10.1097\/JU.0000000000001290.","journal-title":"J Urol"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/modpathol.2016.49","volume":"29","author":"CF Kweldam","year":"2016","unstructured":"Kweldam CF, K\u00fcmmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol. 2016;29:630\u20136. https:\/\/doi.org\/10.1038\/modpathol.2016.49.","journal-title":"Mod Pathol"},{"key":"1143_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41391-024-00802-6","volume":"28","author":"LJ Kroon","year":"2025","unstructured":"Kroon LJ, Remmers S, Hollemans E, Bangma CH, Roobol MJ, van Leenders GJLH. Does prostate cancer without cribriform pattern have metastatic potential? Prostate Cancer Prostatic Dis. 2025;28:342\u20134. https:\/\/doi.org\/10.1038\/s41391-024-00802-6.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAP.0000000000000287","volume":"28","author":"SC Smith","year":"2021","unstructured":"Smith SC, Gandhi JS, Moch H, Aron M, Comp\u00e9rat E, Paner GP, et al. Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. Adv Anat Pathol. 2021;28:1\u20137. https:\/\/doi.org\/10.1097\/PAP.0000000000000287.","journal-title":"Adv Anat Pathol"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euf.2023.08.010","volume":"10","author":"RM Bernardino","year":"2024","unstructured":"Bernardino RM, Sayyid RK, Lajkosz K, Al-Daqqaq Z, Cockburn JG, Chavarriaga J, et al. Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer. Eur Urol Focus. 2024;10:146\u201353. https:\/\/doi.org\/10.1016\/j.euf.2023.08.010.","journal-title":"Eur Urol Focus"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JU.0000000000000526","volume":"203","author":"KJ Ericson","year":"2020","unstructured":"Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance. J Urol. 2020;203:311\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000000526.","journal-title":"J Urol"},{"key":"1143_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/his.13747","volume":"74","author":"M Masoomian","year":"2019","unstructured":"Masoomian M, Downes MR, Sweet J, Cheung C, Evans AJ, Fleshner N, et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology. 2019;74:474\u201382. https:\/\/doi.org\/10.1111\/his.13747.","journal-title":"Histopathology"},{"key":"1143_CR12","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers16112002","volume":"16","author":"E Comp\u00e9rat","year":"2024","unstructured":"Comp\u00e9rat E, Kl\u00e4ger J, Rioux-Leclercq N, Oszwald A, Wasinger G. Cribriform versus Intraductal: How to Determine the Difference. Cancers. 2024;16:2002. https:\/\/doi.org\/10.3390\/cancers16112002.","journal-title":"Cancers"},{"key":"1143_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.eururo.2025.07.021","volume":"88","author":"AJ Vickers","year":"2025","unstructured":"Vickers AJ, Assel M, Dunn RL, MacLennan G, Becker BJ, Riley RD. Guidelines for Meta-analyses and Systematic Reviews in Urology. Eur Urol. 2025;88:421\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.021.","journal-title":"Eur Urol"},{"key":"1143_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70:106\u201319. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028.","journal-title":"Eur Urol"},{"key":"1143_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","volume":"45","author":"TH van der Kwast","year":"2021","unstructured":"van der Kwast TH, van Leenders GJ, Berney DM, Delahunt B, Evans AJ, Iczkowski KA, et al. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol. 2021;45:1118\u201326. https:\/\/doi.org\/10.1097\/PAS.0000000000001728.","journal-title":"Am J Surg Pathol"},{"key":"1143_CR16","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u201399. https:\/\/doi.org\/10.1097\/PAS.0000000000001497.","journal-title":"Am J Surg Pathol"},{"key":"1143_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"1143_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-025-02752-z","volume":"14","author":"JF Tierney","year":"2025","unstructured":"Tierney JF, Burdett S, Fisher DJ. Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance. Syst Rev. 2025;14:84. https:\/\/doi.org\/10.1186\/s13643-025-02752-z.","journal-title":"Syst Rev"},{"key":"1143_CR19","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MKB Parmar","year":"1998","unstructured":"Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815\u201334.","journal-title":"Stat Med"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing Bias in Studies of Prognostic Factors. Ann Intern Med. 2013;158:280\u20136. https:\/\/doi.org\/10.7326\/0003-4819-158-4-201302190-00009.","journal-title":"Ann Intern Med"},{"key":"1143_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2017.03.013","volume":"72","author":"LH Porter","year":"2017","unstructured":"Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol. 2017;72:492\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.013.","journal-title":"Eur Urol"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/PAS.0000000000000691","volume":"40","author":"B Choy","year":"2016","unstructured":"Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, et al. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016;40:1400\u20136. https:\/\/doi.org\/10.1097\/PAS.0000000000000691.","journal-title":"Am J Surg Pathol"},{"key":"1143_CR23","doi-asserted-by":"publisher","unstructured":"Hilibrand AS, Tuac Y, Argun O, Breneman CM, Oh M, Moningi S, et al. Age-specific impact of cribriform pattern in prostate cancer following radical prostatectomy. Clin Med Insights Oncol. 2025;19. https:\/\/doi.org\/10.1177\/11795549251363324","DOI":"10.1177\/11795549251363324"},{"key":"1143_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10147-022-02277-8","volume":"28","author":"Y Tohi","year":"2023","unstructured":"Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, et al. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS\u2013JAPAN study. Int J Clin Oncol. 2023;28:299\u2013305. https:\/\/doi.org\/10.1007\/s10147-022-02277-8.","journal-title":"Int J Clin Oncol"},{"key":"1143_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2025.01.013","volume":"88","author":"RM Bernardino","year":"2025","unstructured":"Bernardino RM, van der Kwast T, Fleshner NE. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eur Urol. 2025;88:123\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2025.01.013.","journal-title":"Eur Urol"},{"key":"1143_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00428-020-02902-9","volume":"478","author":"MA van der Slot","year":"2021","unstructured":"van der Slot MA, Hollemans E, den Bakker MA, Hoedemaeker R, Kliffen M, Budel LM, et al. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome. Virchows Arch. 2021;478:249\u201356. https:\/\/doi.org\/10.1007\/s00428-020-02902-9.","journal-title":"Virchows Arch"},{"key":"1143_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"1143_CR28","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jamaoncol.2025.4125","volume":"11","author":"N Sushentsev","year":"2025","unstructured":"Sushentsev N, Warren AY, Colling R, Verrill C, Pazukhina E, Blyuss O, et al. Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer. JAMA Oncol. 2025;11:1512. https:\/\/doi.org\/10.1001\/jamaoncol.2025.4125.","journal-title":"JAMA Oncol"},{"key":"1143_CR29","doi-asserted-by":"publisher","unstructured":"Bernardino R, Le Guev\u00e9lou J, Autorino R, Gandaglia G, Marra G Re: Nikita Sushentsev, Anne et al. Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. JAMA Oncol. In press. Eur Urol Focus. 2025. https:\/\/doi.org\/10.1016\/j.euf.2025.11.021","DOI":"10.1016\/j.euf.2025.11.021"},{"key":"1143_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.21037\/tau.2017.12.33","volume":"7","author":"CF Kweldam","year":"2018","unstructured":"Kweldam CF, van der Kwast T, van Leenders GJ. On cribriform prostate cancer. Transl Androl Urol. 2018;7:145\u201354. https:\/\/doi.org\/10.21037\/tau.2017.12.33.","journal-title":"Transl Androl Urol"},{"key":"1143_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/his.70046","volume":"88","author":"RB Shah","year":"2026","unstructured":"Shah RB, Varma M, Zhou M, Paner GP, Amin MB, Berney DM, et al. The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate. Histopathology. 2026;88:8\u201323. https:\/\/doi.org\/10.1111\/his.70046.","journal-title":"Histopathology"},{"key":"1143_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41391-024-00818-y","volume":"27","author":"H Zeng","year":"2024","unstructured":"Zeng H, Zhu S, Li J, Chen N, Zhu Y. MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment. Prostate Cancer Prostatic Dis. 2024;27:242\u20133. https:\/\/doi.org\/10.1038\/s41391-024-00818-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2012.201","volume":"26","author":"TL Lotan","year":"2013","unstructured":"Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26:587\u2013603. https:\/\/doi.org\/10.1038\/modpathol.2012.201.","journal-title":"Mod Pathol"},{"key":"1143_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41391-025-01046-8","volume":"29","author":"N Heckmann","year":"2026","unstructured":"Heckmann N, Plage H, Simon R, Lennartz M, Fraune C, Jacobsen F, et al. High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer. Prostate Cancer Prostatic Dis. 2026;29:181\u20138. https:\/\/doi.org\/10.1038\/s41391-025-01046-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41391-024-00910-3","volume":"28","author":"RM Bernardino","year":"2025","unstructured":"Bernardino RM, Yin LB, Lajkosz K, Cockburn JG, Wettstein M, Sayyid RK, et al. Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes. Prostate Cancer Prostatic Dis. 2025;28:187\u201392. https:\/\/doi.org\/10.1038\/s41391-024-00910-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR36","doi-asserted-by":"publisher","unstructured":"Osiecki R, Kozikowski M, Bia\u0142ek L, Pyzlak M, Dobruch J. The presence of cribriform pattern in prostate biopsy and radical prostatectomy is associated with negative postoperative pathological features. Cent Eur J Urol. 2024. https:\/\/doi.org\/10.5173\/ceju.2023.215","DOI":"10.5173\/ceju.2023.215"},{"key":"1143_CR37","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41391-024-00866-4","volume":"28","author":"C Siech","year":"2025","unstructured":"Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Pe\u00f1aranda N, Goyal JA, et al. Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality. Prostate Cancer Prostatic Dis. 2025;28:748\u201354. https:\/\/doi.org\/10.1038\/s41391-024-00866-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41391-022-00600-y","volume":"26","author":"GI Russo","year":"2023","unstructured":"Russo GI, Soeterik T, Puche-Sanz I, Broggi G, Lo Giudice A, De Nunzio C, et al. Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:646\u201354. https:\/\/doi.org\/10.1038\/s41391-022-00600-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1143_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.eururo.2023.03.014","volume":"84","author":"G Marra","year":"2023","unstructured":"Marra G, van Leenders GJLH, Zattoni F, Kesch C, Rajwa P, Cornford P, et al. Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review. Eur Urol. 2023;84:65\u201385. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.014.","journal-title":"Eur Urol"},{"key":"1143_CR40","doi-asserted-by":"publisher","first-page":"175.e1","DOI":"10.1016\/j.urolonc.2024.02.010","volume":"42","author":"S Das","year":"2024","unstructured":"Das S, Luu M, Terris M, Klaassen Z, Kane CJ, Amling C, et al. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era. Urologic Oncol. 2024;42:175.e1\u2013175.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2024.02.010.","journal-title":"Urologic Oncol"},{"key":"1143_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.juro.2016.07.004","volume":"197","author":"L Liesenfeld","year":"2017","unstructured":"Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. J Urol. 2017;197:143\u20138. https:\/\/doi.org\/10.1016\/j.juro.2016.07.004.","journal-title":"J Urol"},{"key":"1143_CR42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMe2309502","volume":"389","author":"A Aparicio","year":"2023","unstructured":"Aparicio A. Biochemical Recurrence in Prostate Cancer \u2014 Tilting the Scale. N Engl J Med. 2023;389:1522\u20133. https:\/\/doi.org\/10.1056\/NEJMe2309502.","journal-title":"N Engl J Med"},{"key":"1143_CR43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389:1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"1143_CR44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","volume":"86","author":"AB Weiner","year":"2024","unstructured":"Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, et al. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2024;86:200\u201310. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.034.","journal-title":"Eur Urol"},{"key":"1143_CR45","doi-asserted-by":"publisher","unstructured":"Zheng R, Tang Y, Daskivich TJ, Amling CL, Aronson WJ, Cooperberg MR, et al. Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results from the SEARCH Database. Eur Urol Oncol. 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.12.009","DOI":"10.1016\/j.euo.2025.12.009"},{"key":"1143_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2024.05.020","volume":"86","author":"V Achard","year":"2024","unstructured":"Achard V, Tombal B. All Biochemical Recurrences Are Equal, but Some Are More Equal than Others. Eur Urol. 2024;86:211\u20132. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.020.","journal-title":"Eur Urol"},{"key":"1143_CR47","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. Eur Urol. 2012;61:480\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.044.","journal-title":"Eur Urol"},{"key":"1143_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","volume":"75","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2019;75:506\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.012.","journal-title":"Eur Urol"},{"key":"1143_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.euo.2023.05.003","volume":"6","author":"G Gandaglia","year":"2023","unstructured":"Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, et al. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool. Eur Urol Oncol. 2023;6:543\u201352. https:\/\/doi.org\/10.1016\/j.euo.2023.05.003.","journal-title":"Eur Urol Oncol"},{"key":"1143_CR50","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/clinpract14020039","volume":"14","author":"E Bologna","year":"2024","unstructured":"Bologna E, Ditonno F, Licari LC, Franco A, Manfredi C, Mossack S, et al. Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX. Clin Pract. 2024;14:508\u201320. https:\/\/doi.org\/10.3390\/clinpract14020039.","journal-title":"Clin Pract"},{"key":"1143_CR51","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.euf.2022.05.005","volume":"8","author":"Z Lone","year":"2022","unstructured":"Lone Z, Benidir T, Rainey M, Nair M, Davicioni E, Gibb EA, et al. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate. Eur Urol Focus. 2022;8:1575\u201382. https:\/\/doi.org\/10.1016\/j.euf.2022.05.005.","journal-title":"Eur Urol Focus"},{"key":"1143_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-01062-8","author":"U Singhal","year":"2025","unstructured":"Singhal U, Jiang R, Proudfoot JA, Chase E, Suresh K, Davicioni E, et al. Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer. Prostate Cancer Prost Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01062-8.","journal-title":"Prostate Cancer Prost Dis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01143-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:43Z","timestamp":1793289763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01143-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01143-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luca Cindolo is associate editor for Prostate Cancer and Prostatic Diseases. The remaining authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}